# Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis

> **NCT07143864** · NA · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Chongqing Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Primary Cutaneous Amyloidosis

## Interventions

- **BIOLOGICAL:** Stapokibart
- **OTHER:** Placebo drug

## Key facts

- **NCT ID:** NCT07143864
- **Lead sponsor:** First Affiliated Hospital of Chongqing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07143864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07143864, "Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07143864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*